Monoclonal gammopathy of undetermined significance (MGUS) care at Mayo Clinic

Your Mayo Clinic care team

Mayo Clinic's MGUS teams are led by hematologists and include other specialists as needed, such as neurologists if nerve damage is suspected, nephrologists to prevent kidney failure and dermatologists if you have skin lesions.

Having all of this specialized expertise in a single place, focused on you, means that you're not just getting one opinion — care is discussed among the team, appointments are scheduled in coordination, and highly specialized MGUS experts are all working together to determine what's best for you.

What might take months to accomplish elsewhere can typically be done in only a matter of days at Mayo Clinic.

Advanced treatment

Researchers at Mayo Clinic coined the term "monoclonal gammopathy of undetermined significance" (MGUS) when they originally identified this condition. Mayo Clinic specialists have experience distinguishing MGUS from more-advanced plasma cell disorders. That's important in determining prognosis and treatment.

Mayo Clinic has developed a risk-assessment model that can predict the risk of progression of MGUS to multiple myeloma. Mayo Clinic researchers also are studying how to prevent progression and how risk factors for the disease may affect treatment.

Mayo Clinic in Rochester, Minn., Mayo Clinic in Jacksonville, Fla., and Mayo Clinic in Scottsdale, Ariz., are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Expertise and rankings

Mayo Clinic's MGUS experts provide comprehensive care for more than 3,500 people with MGUS each year.

  • Teamwork. A specialist in blood diseases (hematologist) will oversee your care. Other specialists — including neurologists, nephrologists and dermatologists — participate in your care as needed.
  • The latest techniques and technology. Mayo Clinic pathologists are skilled in the testing and identification of the M protein and determining the potential risk of progression to cancer.
  • Research advances. Mayo Clinic researchers coined the term "monoclonal gammopathy of undetermined significance (MGUS)" when they identified the condition. These experts are studying MGUS to better understand it and to improve treatment options.

Mayo Clinic in Rochester, Minn., Mayo Clinic in Jacksonville, Fla., and Mayo Clinic in Scottsdale, Ariz., are ranked among the Best Hospitals for cancer by U.S. News & World Report.

Locations, travel and lodging

Mayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states.

For more information on visiting Mayo Clinic, choose your location below:

Costs and insurance

Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people.

In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals, or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need.

Learn more about appointments at Mayo Clinic.

Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card.

July 29, 2017
References
  1. Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed Feb. 17, 2016.
  2. Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed Feb. 17, 2016.
  3. Ferri FF. Monoclonal gammopathy of undetermined significance (MGUS). In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016. https://www.clinicalkey.com. Accessed Feb. 17, 2016.
  4. Glavey SV, et al. Monoclonal gammopathy: The good, the bad and the ugly. Blood Reviews. In press. http://dx.doi.org/10.1016/j.blre.2015.12.001. Accessed Feb. 18, 2016.
  5. Goldman L, et al., eds. Plasma cell disorders. In: Goldman-Cecil Medicine. 25th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 11, 2016.
  6. AskMayoExpert. Monoclonal gammopathy of undetermined significance (MGUS) prevalence. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  7. Kyle RA, et al. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematology/Oncology Clinics of North America. 2014;28:775.
  8. Sethi S, et al. Spectrum of manifestations of monoclonal gammopathy-associated renal syndromes. Current Opinion in Nephrology and Hypertension. 2016;25:127.
  9. AskMayoExpert. Monoclonal gammopathy of undetermined significance (MGUS). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  10. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 13, 2016.

Monoclonal gammopathy of undetermined significance (MGUS)